Imatinib mesylate


Entry
D01441                      Drug                                   
Name
Imatinib mesylate (USAN);
Imatinib mesilate (JAN);
Gleevec (TN);
Glivec (TN)
Product
GLEEVEC (Novartis Pharmaceuticals Corporation)
  Generic
IMATINIB MESYLATE (Amneal Pharmaceuticals LLC), IMATINIB (Dr.Reddy's Laboratories), IMATINIB MESYLATE (Golden State Medical Supply), IMATINIB MESYLATE (Mylan Institutional), IMATINIB MESYLATE (Mylan Pharmaceuticals), IMATINIB MESYLATE (American Health Packaging), IMATINIB MESYLATE (Apotex Corp), IMATINIB MESYLATE (Archis Pharma LLC), IMATINIB MESYLATE (Areva Pharmaceuticals), IMATINIB MESYLATE (Armas Pharmaceuticals), IMATINIB MESYLATE (Armas Pharmaceuticals), IMATINIB MESYLATE (Ascend Laboratories), IMATINIB MESYLATE (Aurobindo Pharma Limited), IMATINIB MESYLATE (AvPAK), IMATINIB MESYLATE (BluePoint Laboratories), IMATINIB MESYLATE (Breckenridge Pharmaceutical), IMATINIB MESYLATE (Bryant Ranch Prepack), IMATINIB MESYLATE (Bryant Ranch Prepack), IMATINIB MESYLATE (CELLTRION USA), IMATINIB MESYLATE (Cadila Healthcare Limited), IMATINIB MESYLATE (Major Pharmaceuticals), IMATINIB MESYLATE (NorthStar RxLLC), IMATINIB MESYLATE (Qilu Pharmaceutical), IMATINIB MESYLATE (Sun Pharmaceutical Industries), IMATINIB MESYLATE (Teva Pharmaceuticals USA), IMATINIB MESYLATE (West-Ward Pharmaceuticals Corp), IMATINIB MESYLATE (Wockhardt USA LLC.), IMATINIB MESYLATE (Zydus Pharmaceuticals (USA))
Formula
C29H31N7O. CH4SO3
Exact mass
589.2471
Mol weight
589.7084
Structure
Simcomp
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG03161  BCR-ABL inhibitor
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Therapeutic category: 4291
ATC code: L01EA01
Chemical structure group: DG00710
Product (DG00710): D01441<JP/US>
Efficacy
Antineoplastic, Tyrosine kinase inhibitor
  Disease
Chronic myeloid leukemia (Philadelphia chromosome positive) [DS:H00004]
Acute lymphoblastic leukemia (Philadelphia chromosome positive) [DS:H00001]
Myelodysplastic/myeloproliferative diseases [DS:H02410]
Mastocytosis [DS:H01511]
Hypereosinophilic syndrome (FIP1L1-PDGFRA positive) [DS:H01599]
Chronic eosinophilic leukemia (FIP1L1-PDGFRA positive) [DS:H01590]
Gastrointestinal stromal tumors (KIT positive) [DS:H01591]
Target
BCR-ABL [HSA_VAR:25v1] [HSA:25] [KO:K06619]
FIP1L1-PDGFRA [HSA:5156] [KO:K04363]
KIT (CD117) [HSA:3815] [KO:K05091]
  Network
N10001  First-generation tyrosine kinase inhibitor to BCR-ABL fusion
  Pathway
hsa04010  MAPK signaling pathway
hsa05200  Pathways in cancer
hsa05220  Chronic myeloid leukemia
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Structure map
map07045  Antineoplastics - protein kinase inhibitors
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01EA BCR-ABL tyrosine kinase inhibitors
     L01EA01 Imatinib
      D01441  Imatinib mesylate (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Imatinib
    D01441  Imatinib mesylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D01441  Imatinib mesylate (USAN); Imatinib mesilate (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG03161  BCR-ABL inhibitor
    DG00710  Imatinib
     D01441  Imatinib mesylate
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG00710  Imatinib
     D01441  Imatinib mesylate
Drug classes [BR:br08332]
 Antineoplastic
  DG03161  BCR-ABL inhibitor
   D01441  Imatinib mesylate
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   PDGFR family
    FIP1L1-PDGFRA
     D01441  Imatinib mesylate (USAN) <JP/US>
    KIT (CD117)
     D01441  Imatinib mesylate (USAN) <JP/US>
  Non-receptor tyrosine kinases
   ABL family
    BCR-ABL [HSA_VAR:25v1]
     D01441  Imatinib mesylate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D01441
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D01441
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D01441
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D01441
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D01441
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D01441
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG03161  BCR-ABL inhibitor
    DG00710  Imatinib
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG00710  Imatinib
Other DBs
CAS: 220127-57-1
PubChem: 7848504
ChEBI: 31690
LigandBox: D01441
NIKKAJI: J1.337.144J
KCF data

ATOM        42
            1   C8x C    33.4600  -13.6500
            2   C8y C    33.4600  -12.2500
            3   C8x C    32.2700  -11.5500
            4   C8x C    31.0100  -12.2500
            5   C8y C    31.0100  -13.6500
            6   C8x C    32.2700  -14.3500
            7   C5a C    29.8200  -14.3500
            8   N1b N    28.6300  -13.6500
            9   C8y C    27.4400  -14.3500
            10  C8x C    26.1800  -13.6500
            11  C8y C    24.9900  -14.3500
            12  C8y C    24.9900  -15.7500
            13  C8x C    26.1800  -16.4500
            14  C8x C    27.4400  -15.7500
            15  N1b N    23.8000  -13.7200
            16  C8y C    22.5400  -14.4200
            17  N5x N    21.3500  -13.7200
            18  C8y C    20.1600  -14.4200
            19  C8x C    20.1600  -15.8200
            20  C8x C    21.3500  -16.5200
            21  N5x N    22.5400  -15.8200
            22  C8y C    18.9000  -13.7200
            23  C8x C    18.9000  -12.3200
            24  N5x N    17.7100  -11.6200
            25  C8x C    16.5200  -12.3200
            26  C8x C    16.5200  -13.7200
            27  C8x C    17.7100  -14.4200
            28  C1b C    34.6500  -11.5500
            29  N1y N    35.9100  -12.2500
            30  C1x C    35.9100  -13.6500
            31  C1x C    37.1000  -14.3500
            32  N1y N    38.2900  -13.6500
            33  C1x C    38.2900  -12.2500
            34  C1x C    37.1000  -11.5500
            35  C1a C    39.5500  -14.3500
            36  O5a O    29.8200  -15.7500
            37  C1a C    23.8000  -16.4500
            38  S4a S    34.9300  -16.5900
            39  O1d O    34.9300  -15.1900
            40  O1d O    34.9300  -17.9900
            41  C1a C    33.5300  -16.5900
            42  O1d O    36.3300  -16.5900
BOND        45
            1    18  19 2
            2    19  20 1
            3    20  21 2
            4    21  16 1
            5     3   4 2
            6    18  22 1
            7     4   5 1
            8     5   6 2
            9     6   1 1
            10    9  10 2
            11   10  11 1
            12   22  23 2
            13   23  24 1
            14   24  25 2
            15   25  26 1
            16   26  27 2
            17   27  22 1
            18   11  12 2
            19    2  28 1
            20   12  13 1
            21   28  29 1
            22   13  14 2
            23   14   9 1
            24   11  15 1
            25    5   7 1
            26   29  30 1
            27   30  31 1
            28   31  32 1
            29   32  33 1
            30   33  34 1
            31   34  29 1
            32   15  16 1
            33   32  35 1
            34    7  36 2
            35    7   8 1
            36   12  37 1
            37    1   2 2
            38    8   9 1
            39    2   3 1
            40   16  17 2
            41   17  18 1
            42   38  39 2
            43   38  40 2
            44   38  41 1
            45   38  42 1